News Releases

16 Aug '2021
First Patient Enrolled to the Phase 2 Trial, which will Evaluate Single-Agent Aspacytarabine in Second Line Relapsed/Refractory AML and MDS Study sponsored by Groupe Francophone des Myélodysplasies, the French Study Group of the European Myelodysplastic Syndromes Cooperative Group AIRPORT CITY,
11 Aug '2021
MONMOUTH JUNCTION, N.J. , Aug. 11, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (“Advaxis” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products, announced that it has received a letter
Displaying 1 - 10 of 19